Pfizer spends billions on another takeover

Pfizer is boosting its pipeline with a $5.4 billion deal for blood disorder drugmaker Global Blood Therapeutics, the latest in a series of acquisitions to combat a potential slowdown in COVID products demand as cases fall.

---